Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064152 | 1.00 | TSHR (0.49) | TSHRALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL11838769 | 0.90 | MMP12 (0.54) | TSHRALDH1A1MAPTHTT | |
| SCHEMBL10482476 | 0.86 | AOC3 (0.47) | TSHRALDH1A1KMT2AMEN1HTT | |
| Hydrochloric Acid SCHEMBL8190926 | 0.84 | ALDH1A1 (0.47) | TSHRALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL6450579 | 0.83 | TSHR (0.44) | TSHRALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL5870453 | 0.82 | TSHR (0.46) | TSHRKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL21953013 | 0.82 | SLC6A2 (0.50) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL8255779 | 0.82 | TSHR (0.46) | TSHRKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL3663595 | 0.81 | PPARG (0.46) | TSHRKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL121728 | 0.81 | MAPT (0.61) | ALDH1A1MAPTKMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3788039-B1 | FACTOR XIIA INHIBITORS | UNIV LEEDS INNOVATIONS LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2021-03-25 | — | — | US | disclosed |
| EP-3788039-A1 | FACTOR XIIA INHIBITORS | University of Leeds (GB) | 2021-03-10 | — | — | EP | disclosed |
| CN-112204023-A | Factor XIIa inhibitors | 利兹大学 | 2021-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | F11, F13B, F12 | TSHR 2718/4885ALDH1A1 1427/4885MAPT 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.